新宙邦(300037.SZ)一季度淨利潤預增210%-230%
格隆匯3月28日丨新宙邦(300037.SZ)公佈,預計2022年一季度歸屬於上市公司股東的淨利潤4.82億元-5.13億元,同比增長210%-230%。
報吿期內,預計公司主營業務利潤相比去年同期上升。主要受益於一方面新能源汽車行業發展態勢持續向好,公司電池化學品業務市場需求旺盛,產銷量同比大幅增加帶動公司盈利能力提升,另一方面公司有機氟化學品業務主營產品及在半導體等領域含氟新產品銷售規模擴大,促進公司經營業績提升。
報吿期公司非經常性損益約1000萬,比上年同期減少約900萬,主要是2022年一季度單項計提應收賬款減值準備衝回數同比大幅減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.